Study results indicate that mutation strength may shape both tumor–immune system interactions and immunotherapy response.
Abstract: Non-small cell lung cancer (NSCLC) remains the major contributor to global deaths annually. A slow and long screening and diagnostic process may lower 5-year survival rates. In cancer ...
Researchers at LUMC have made a breakthrough in understanding PALB2 mutations, an important cause of hereditary breast cancer ...
The SCN2A Foundation today announced a research collaboration with Unravel Biosciences, Inc., an AI-enabled therapeutics ...
In mantle cell lymphoma (MCL), an aggressive form of B-cell non-Hodgkin lymphoma, TP53 mutations are known to affect patients’ prognosis—but questions remain. What does the heterogeneity of TP53 ...